Table 3.
mRNA-encoded antibody fragments in preclinical studies.
| Antibody | Target | Format | Model | Outcome | Ref |
|---|---|---|---|---|---|
| RiboMABs | CD3 × CLDN6 CLDN18.2 × CD3 EpCAM × CD3 CD3 × (CLDN6)2 |
Bs (scFv)2 Fab-(scFv)2 |
Human PBMC-engrafted NSG mice bearing s.c. human ovarian cancer xenografts | Eradication of tumors (200–300 mm3) after one. i.v. infusion a week for 3 weeks | [49] |
| VNA-BoNTA | Botulism neurotoxin A | Bp (VHH)2 + ABP | CD1 mice receiving a lethal dose of BoNTA | Survival when treated up to 6 h post-intoxication with i.v. VNA-BoNTA | [52] |
| VNA-Stx2 | E. coli Shiga toxin | Bs (VHH)2 + ABP | CD1 mice receiving a lethal dose of BoNTA | Negative control. No surviving mice in this group | [52] |
| RSV aVHH | RSV F protein | VHH + GPI anchor | BALB/c mice inoculated i.n. with RSV 1 day post-treatment | RSV titers significantly lower after i.t. aerosol mRNA administration | [53] |
| RiboBiFE | Mouse FcγRIV x influenza A M2e | Bs (VHH)2 | C57BL/6 mice challenged with i.n. lethal dose of influenza virus 4 h post-treatment | 100% survival in wild-type mice receiving i.t. mRNA, 0% in mice FcγRIV-/- | [54] |
Abbreviations: ABP, albumin-binding peptide; BoNTA, botulism neurotoxin A; Bp, biparatopic; Bs, bispecific; CLDN, claudin; EpCAM, epithelial cell adhesion molecule; Fab, antigen-binding fragment GPI, glycosylphosphatidylinositol; i.n., intranasal; i.t., intratracheal; i.v., intravenous; PBMC, peripheral blood mononuclear cell; RiboBiFE, mRNA-encoded bispecific Fc-receptor engaging; RiboMAB, mRNA-encoded antibody; RSV, respiratory syncytial virus; M2e, matrix protein 2 ectodomain; VNA, VHH-based neutralizing agent.